Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of BI 1595043 in Healthy Men
NCT04789304Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1595043 in inflammatory bowel disease (IBD) and Crohn's disease (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events (AEs) up to 30 days. Started Apr 2021; status: completed.
02
Drugs
BI 1595043
03
Conditions
inflammatory bowel disease (IBD)Crohn's disease
Beyond the preview
Go deeper on NCT04789304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789304.